A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

toxicities

Outcome Time Frame:

6 months

Safety Issue:

Yes

Principal Investigator

Jonathan Lewis, MD, PhD

Investigator Role:

Study Director

Investigator Affiliation:

ZIOPHARM Oncology, Inc

Authority:

United States: Food and Drug Administration

Study ID:

IPM1001

NCT ID:

NCT00421135

Start Date:

February 2006

Completion Date:

October 2007

Related Keywords:

• Advanced Cancer
• Neoplasms

Name	Location
	Fountain Valley, California  92708
	Flint, Michigan  48532